Literature DB >> 1311627

Molecular markers for the diagnosis and prognosis of lung cancer.

A F Gazdar1.   

Abstract

Molecular probes for lung cancer have greatly increased the understanding of the biology of this disease and the preneoplastic changes that precede it. They have confirmed and extended the clinical, pathologic, and biologic reasons for the primary division of lung cancers into small cell and non-small cell lung cancer types. Many molecular changes are present in lung cancers and involve dominant oncogenes and recessive growth regulatory genes. Clinical application of these markers will aid diagnosis, classification, and clinical management.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311627     DOI: 10.1002/1097-0142(19920315)69:6+<1592::aid-cncr2820691315>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Detection of P53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications.

Authors:  M A Kuczyk; J Serth; C Hervatin; H Arndt; L Derendorf; W F Thon; U Jonas
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

2.  Protein binding modulates inhibition of the epidermal growth factor receptor kinase and DNA synthesis by tyrphostins.

Authors:  R Hoffman; I F Dennis; J Donaldson
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.

Authors:  J Serth; M A Kuczyk; C Bokemeyer; C Hervatin; R Nafe; H K Tan; U Jonas
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.